ASH 2022 | Phase I study of HPN217 in patients with R/R multiple myeloma
Al-Ola Abdallah
• 11 Dec 2022
Al-Ola Abdallah, MD, University of Kansas Medical Center, Westwood, KS, outlines the design and results of a Phase I study (NCT04184050) investigating the efficacy of HPN217, a tri-specific T-cell activating construct, in patients with relapsed/refractory (R/R) multiple myeloma. Dr Abdallah explains that HPN217 was well tolerated and resulted in durable responses, and suggests that this drug may represent a promising option for patients with prior exposure to BCMA-targeted agents. This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
